SPOTLIGHT -
SUNSHINE and SUNRISE Trials in HS
An expert in dermatology reviews the phase 3 SUNSHINE and SUNRISE trials evaluating the use of secukinumab given in 2-week intervals in patients with HS and shares clinical pearls for managing the condition.
Read More
Emerging Agents for the Management of HS
An expert in dermatology highlights emerging biologic therapy for the management of HS.
Role of Immunomodulation in HS Treatment
Renata Block, MMS, PA-C, comments on the use of biologic agents as part of immunomodulatory therapy for HS treatment.
Approaching Treatment and Addressing Unmet Needs for Mild-to-Moderate HS
An expert in dermatology reviews the current standard of care for treating patients with mild-to-moderate HS and discusses unmet needs in the clinical management of the condition.
Overview of Hidradenitis Suppurativa (HS): A Multifactorial Disease
Renata Block, MMS, PA-C, provides insight on the prevalence, symptoms, and predisposing factors that contribute to hidradenitis suppurativa (HS).
